Immunotherapy in Hodgkin and Non-Hodgkin Lymphoma: Innate, Adaptive and Targeted Immunological Strategies

The concept of harnessing the immune system to defend against cancer has been recognized since around the turn of the last century when Dr. William Coley advocated cancer immunotherapy with bacterial toxins [1,2]. The advancement of molecular medicine and increased understanding of tumor-immune cell interactions has led to the development of novel immunotherapeutic strategies that have been implemented for the treatment of a wide variety of malignancies. Lymphoma, however, is somewhat unique in that it is a malignancy of the immune system; hence, the malignant cell interacts with the immune system, regulates the host immune system via cytokine signaling, and orchestrates mechanisms to evade the antitumor immune response [3 –6].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research